Cancer Screening and Prevention Research Group

Who we are

The Cancer Screening and Prevention Research Group (CSPRG) is an internationally renowned research group based at Imperial College London. Established in 2008 by the late Professor Wendy Atkin and now headed by Professor Amanda Cross, the group has extensive expertise in conducting clinical trials and includes an experienced team of research scientists, statisticians, clinical trial managers, data analysts and data managers.

What we do

The research focus of the Cancer Screening and Prevention Research Group (CSPRG) is bowel cancer, also known as colorectal cancer. In the UK, over 41,000 people are diagnosed with bowel cancer every year and 16,000 people die from the disease. Through our research we hope to reduce the numbers of people receiving a diagnosis of bowel cancer and dying from this disease. Much of our work focuses on how to help make bowel cancer screening and surveillance programmes more effective and acceptable for participants, and more efficient for the NHS, and other health services internationally.

How we do it

We conduct large-scale studies by either recruiting people from participating healthcare providers or by collating and analysing data collected from UK-based hospitals and other data providers.

How we are funded

We receive funding from the UK Government, through the Department of Health and research councils, as well as charities including Cancer Research UK, 40tude and the Bobby Moore Fund. The Faecal Immunochemical Tests (FIT) for the FIT for Follow-Up study were provided in kind by Eiken Chemical Co. Ltd and Mast Group LtdKeyMed Ltd (now Olympus) provided funding in 1994 for a pilot study in preparation for the UK Flexible Sigmoidoscopy Screening Trial (UKFSST).

Information we may hold about you and your options if you wish to opt out

If you have taken part in a bowel cancer screening programme, gone to your GP with symptoms suggestive of bowel cancer, agreed to participate in one of our studies or had bowel cancer treatment on the NHS, we may retain some information about you. Our Patient Data page provides further details on how we process this data and your options if you wish to opt out.

For researchers – requesting data

Data used in CSPRG research was collected subject to the informed consent of the participants and / or under section 251 support. Access to the individual-level anonymised data will only be granted in line with the relevant informed consent form or section 251 support, subject to approval by the appropriate research ethics committee, Health Research Authority (HRA) and HRA Confidentiality Advisory Group (HRA-CAG) as required, under a formal data sharing agreement.

To discuss a request for data please contact the CSPRG by completing the contact form with the following information: the proposed study objectives, the data you require and timelines for completion of the research.

We will shortly be recruiting a clinical fellow for 12 months for the National #LynchSyndrome genomics and cancer Project with @NHSEngland @NHSgms @StMarksHospital let me know if you are interested! Thanks @LynchSyndromeUK @bowelcanceruk

Interested in the #EarlyDetection and #Diagnosis? Find out if you could be eligible to receive up to £2.5m in funding to transform how and when pre-cancerous states are diagnosed –

NHS patients and visitors must continue to #WearAMask and follow social distancing measures in healthcare settings.

Please help keep everyone safe.

On this #freedomday, please keep vulnerable people safe & be considerate of people with cancer who may not be as protected from the vaccine as others.

✅Please keep masks in crowded spaces
✅Please keep your distance
✅Please get the vaccine

Back by popular demand🤩 Black Lives Matter in Science and Medicine pt 2 @imperialasone @ImperialMed are excited to welcome back @Prof_Andrisse to @imperialcollege following his fantastic talk last year
Sign up👉
#BlackInTheIvory #BlackInSTEM #BlackinCancer

Load More...